Compare Cytokinetics Inc (CYTK) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Tapestry, Inc. — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Tapestry, Inc. trades at $115.82 (market cap $22.62B). The key difference: Tapestry, Inc. is far larger — about 2.7× Cytokinetics Inc's market cap, and Tapestry, Inc. pays a 1.63% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Tapestry, Inc. for 70 Days on average.
| CYTK | TPR | |
|---|---|---|
Market Cap | $8.50B | $22.62B |
Volume | 2,395,556 | 2,093,865 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $164.78 |
52-Week Low | $54.76 | $98.81 |
Typical Hold Time | 19 Days | 70 Days |
Enterprise Value | $8.60B | $25.42B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
TPR trades at $115.82, down 0.78% today, with a bearish technical signal but strong analyst support (73% buy ratings). The company shows robust profitability with 77.82% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights international growth in China and Europe, though the stock faces headwinds from tariff risks and Kate Spade execution challenges.
Outlook remains positive with a $174.64 consensus price target suggesting 51% upside, supported by fiscal 2027 margin expansion targets. Key risks include tariff pressures, premium valuation (P/E 15.6), and recent net cash outflows. The stock presents a growth opportunity if international momentum continues and margin targets are achieved.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
